INS and metabolic dysfunction-associated steatohepatitis: These observations indicate that Liraglutide is a well-tolerated disease-modifying intervention leading to histological resolution of NASH,154,155 reducing metabolic dysfunction, IR, and lipotoxicity in the pathogenesis of NASH.156 Another phase 2 study (NCT01399645) was conducted to test the effects of insulin vs. Liraglutide therapy on hepatic fat in patients with T2DM inadequately controlled with Metformin therapy.